Skip to main content
. 2017 Jun 10;108(7):1394–1404. doi: 10.1111/cas.13271

Figure 3.

Figure 3

Identification of KRAS as a target of microRNA (miR)‐532‐5p in lung adenocarcinoma cells. (a) Quantitative RT‐PCR and Western blot analyses of KRAS in miR‐532‐5p‐introduced NCI‐H23 and NCI‐H1299 cells. Rel. exp., relative expression. (b) Dual luciferase assay using reporter constructs carrying wild‐type (wt) or mutant (mut) sequences of the KRAS 3′‐UTR in NCI‐H23 cells transiently transfected with miR‐532‐5p mimics or negative control (NC). (c) Colorimetric assay of four lung adenocarcinoma cell lines with and without KRAS mutations. Cells were analyzed at 96 h after transfection with either miR‐532‐5p mimics or two independent siRNAs against KRAS. All data shown represent mean ± SD of three independent experiments. *P < 0.05; **P < 0.01, two‐tailed Student's t‐test.